that's why tonight i want to look at quinn tiles. letter q. i describe it as arms dealer to the pharmaceutical industry. major focus on late stage clinical trials. whereby oh tech firms spend most of the money to bring the most promising drug candidates to market. it is the largest contract research organization out there. call them cros. with big farm a outsourcing research and development, it stands to benefit enormously. if you want a drug approved, go to quinn tiles for clean data, accuracy and speed the fda wants to see. they reported end of october and delivered strong results. in line revenues up 13.8%, $10.75 billion backlog. that means they have way more business than they can handle. ultra high quality problem. they'll work that out. private equity shareholder, sold at 58.20. the company bought back 4.3 million of the shares. highly unusual. since then, stocks have bounced between 56 and 58. broke out over 59 today. could be more up side. give us 17% gain since end of may. let's check with tom pike, ceo, to hear more about how his co